Skip to main content
SpringerLink
Log in

Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues

Facts and Controversies

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Chronic lymphocytic leukaemia (CLL) is a neoplastic disease of unknown aetiology characterised by an absolute lymphocytosis in peripheral blood and bone marrow. The disease is diagnosed most commonly in the elderly with the median age at diagnosis being about 65 years. The purine nucleoside analogues (PNAs) fludarabine, cladribine (2-chlorodeoxyadenosine) and pentostatin (2′-deoxycoformycin) are highly active in CLL, both in previously treated and in refractory or relapsed patients. These three agents share similar chemical structures and mechanisms of action such as induction of apoptosis. However, they also exhibit significant differences, especially in their interactions with enzymes involved in adenosine and deoxyadenosine metabolism. Recent randomised studies suggest that fludarabine and cladribine have similar activity in CLL. However, clinical observations indicate the existence of cross-resistance between fludarabine and cladribine. Patients who received PNAs as their initial therapy and achieved long-lasting response can be successfully retreated with the same agent. PNAs administered in combination with other chemotherapeutic agents and/or monoclonal antibodies may produce higher response rates, including complete response (CR) or molecular CR, compared with PNAs alone or other treatment regimens. Management decisions are more difficult in elderly patients because of the apparent increase in toxicity of PNAs in this population. In elderly patients, we recommend chlorambucil as the first-line treatment, with PNAs in lower doses in refractory or relapsed patients. Myelosuppression and infections, including opportunistic varieties, are the most frequent adverse effects in patients with CLL treated with PNAs. Therefore, some investigators recommend routine antibacterial and antiviral prophylaxis during and after PNA treatment. This review presents current results and treatment strategies with the use of PNAs in CLL, especially in elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl) 2004; 13: 279–87

    Article  CAS  Google Scholar 

  2. Kalil N, Cheson BD. Management of chronic lymphocytic leukemia. Drugs Aging 2000; 16: 9–27

    Article  PubMed  CAS  Google Scholar 

  3. Robak T. Therapy of chronic lymphocytic leukemia with purine and monoclonal antibodies. Transfus Apher Sci 2005; 32: 33–44

    Article  PubMed  Google Scholar 

  4. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER Cancer Statistics Review 1975–2001. Bethesda (MD): National Cancer Institute [online]. Available from URL: http://seer.cancer.gov/csr/1975_2000 [Accessed 2005 Nov 18]

  5. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1799–801

    Article  PubMed  CAS  Google Scholar 

  6. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–7

    PubMed  CAS  Google Scholar 

  7. French Cooperative Group on Chronic Lymphocytic Leukemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990; 76: 45–57

    Article  Google Scholar 

  8. Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991; 78: 895–9

    PubMed  CAS  Google Scholar 

  9. Jaksic B, Brugiatelli M, Krc I, et al. High dose chlorambucil versus Binet’s modified cyclophosphamide, doxorubicin, vincristine and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia: results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997; 79: 2107–14

    Article  PubMed  CAS  Google Scholar 

  10. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723–9

    PubMed  CAS  Google Scholar 

  11. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–7

    Article  PubMed  CAS  Google Scholar 

  12. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998; 338: 1506–14

    Article  PubMed  CAS  Google Scholar 

  13. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1015–27

    Article  PubMed  CAS  Google Scholar 

  14. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463–74

    PubMed  CAS  Google Scholar 

  15. Zinzani PL. Non-Hodgkin’s lymphoma: the evolving role of purine analogues. Best Pract Res Clin Haematol 2002; 15: 505–16

    Article  PubMed  CAS  Google Scholar 

  16. Johnson SA, Oscier DG, Leblond V. Waldenstrom’s macroglobulinaemia. Blood Rev 2002; 16: 175–84

    Article  PubMed  CAS  Google Scholar 

  17. Evens AM, Gartenhaus RB. Treatment of T-cell non-Hodgkin’s lymphoma. Curr Treat Options Oncol 2004; 5: 289–303

    Article  PubMed  Google Scholar 

  18. Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukemia. Expert Opin Pharmacother 2004; 5: 1523–33

    Article  PubMed  CAS  Google Scholar 

  19. Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma 2003; 44: 391–409

    Article  PubMed  CAS  Google Scholar 

  20. Pastor-Anglada M, Molina-Arcas M, Casado FJ, et al. Nucleoside transporters in chronic lymphocytic leukemia. Leukemia 2004; 18: 385–92

    Article  PubMed  CAS  Google Scholar 

  21. Molina-Areas N, Marce S, Villamor N, et al. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 2005; 19: 64–8

    Google Scholar 

  22. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogues. Pharmacol Ther 1991; 49: 239–68

    Article  PubMed  CAS  Google Scholar 

  23. Pettit AR. Mechanism of action of purine analogues in chronic lymphocytic leukemia. Br J Haematol 2003; 121: 692–702

    Article  Google Scholar 

  24. Genini D, Adachi S, Chao O, et al. Deoxyadenosine analogs induced programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537–43

    PubMed  CAS  Google Scholar 

  25. Marzo I, Perez-Galan P, Rubio-Felix D, et al. Cladribine induces apoptosis in human leukemia cells by caspase dependent and independent pathways acting on mitochondria. Biochem J 2001; 359: 537–46

    Article  PubMed  CAS  Google Scholar 

  26. Klopfer A, Hasenjager A, Belka C, et al. Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway. Oncogene 2004; 16: 9408–18

    Article  CAS  Google Scholar 

  27. Johnston JB, Daeninck P, Verburg L, et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997; 26: 435–49

    PubMed  CAS  Google Scholar 

  28. Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein activating factor-1 mediated caspase pathway. J Biol Chem 2000; 275: 29–34

    Article  PubMed  CAS  Google Scholar 

  29. Adkins JC, Peters DH, Markham A. Fludarabine: an update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005–37

    PubMed  CAS  Google Scholar 

  30. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952–6

    Article  PubMed  CAS  Google Scholar 

  31. Aldinucci D, Poletto D, Lorenzon D, et al. CD26 expression correlates with a reduced sensitivity to 2′-deoxycoformycin induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. Clin Cancer Res 2004; 10: 508–20

    Article  PubMed  CAS  Google Scholar 

  32. Niitsu N, Yamaguchi Y, Umeda M, et al. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2′-deoxycoformycin and 2′-deoxyadenosine: association with dATP-dependent activation of caspase-3. Blood 1998; 92: 3368–75

    PubMed  CAS  Google Scholar 

  33. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinetics 2002; 41: 93–103

    Article  CAS  Google Scholar 

  34. Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with ‘low-grade’ non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999; 17: 1574–9

    PubMed  CAS  Google Scholar 

  35. Boogaerts MA. Oral fludarabine therapy in chronic lymphocytic leukemia: increased convenience. Hematol J 2004; 5Suppl. 1: S31–7

    Article  PubMed  CAS  Google Scholar 

  36. Robak T. Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2001; 40: 551–64

    Article  PubMed  CAS  Google Scholar 

  37. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res 1991; 51: 5570–2

    PubMed  CAS  Google Scholar 

  38. Liliemark J, Albertioni F, Hassan M, et al. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10: 1514–8

    PubMed  CAS  Google Scholar 

  39. Saven A, Cheung WK, Smith I, et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 1996; 14: 978–83

    PubMed  CAS  Google Scholar 

  40. Lindemalm S, Savic RM, Karlsson MO, et al. Application of population pharmacokinetics to cladribine. BMC Pharmacol 2005 Mar 9; 5(1): 4

    Article  PubMed  CAS  Google Scholar 

  41. O’Dwyer PJ, Wagner B, Leyland-Jones B, et al. 2′-deoxycoformycin (pentostatin) for lymphoid malignancies: rational development of an active new drug. Ann Intern Med 1988; 108: 733–43

    PubMed  Google Scholar 

  42. Begleiter A, Wang H, Verburg L, et al. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia 1996; 10: 1959–65

    PubMed  CAS  Google Scholar 

  43. Szmigielska-Kaplon A, Ciesielska E, Szmigiero L, et al. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 2002; 68: 370–5

    Article  PubMed  CAS  Google Scholar 

  44. Smolewski P, Szmigielska-Kaplon A, Cebula B, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005; 46: 87–100

    Article  PubMed  CAS  Google Scholar 

  45. Bellosillo B, Villamor N, Colomer D, et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836–43

    PubMed  CAS  Google Scholar 

  46. Szmigielska-Kaplon A, Smolewski P, Najder M, et al. Evaluation of apoptosis induced in vitro by cladribine (cladribine) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. Ann Hematol 2002; 81: 508–13

    Article  PubMed  CAS  Google Scholar 

  47. Klein A, Miera O, Bauer O, et al. Chemosensitivity of B-cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia 2000; 14: 40–6

    Article  PubMed  CAS  Google Scholar 

  48. Robak T, Blasinska-Morawiec M, Blonski J, et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999; 62: 49–56

    Article  PubMed  CAS  Google Scholar 

  49. Bergmann L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4: 371–5

    PubMed  CAS  Google Scholar 

  50. Seymour JF, Kurzrock R, Freireich EJ, et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906–11

    PubMed  CAS  Google Scholar 

  51. Anaissie EJ, Kontoyiannis DP, O’Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559–66

    PubMed  CAS  Google Scholar 

  52. Cheson BD. Infections and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431–48

    PubMed  CAS  Google Scholar 

  53. Van den Neste E, Delannoy A, Vandercam B. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996; 56: 235–40

    Article  Google Scholar 

  54. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukaemia: clinical, therapeutic and prognostic features. Blood 2000; 95: 2786–92

    PubMed  CAS  Google Scholar 

  55. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432–8

    PubMed  CAS  Google Scholar 

  56. Leporrier M, Chevret S, Cazin B, et al. French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–25

    Article  PubMed  CAS  Google Scholar 

  57. Leporrier M, Reman O, Troussard X. Pure red-cell aplasia with fludarabine for chronic lymphocytic leukemia [letter]. Lancet 1993; 342: 555

    Article  PubMed  CAS  Google Scholar 

  58. Robak T, Kasznicki M, Blonski JZ, et al. Pure red cell aplasia with chronic lymphocytic leukaemia treated with cladribine. Br J Haematol 2001; 112: 1083–5

    Article  PubMed  CAS  Google Scholar 

  59. Kroft SH, Tallman MS, Shaw JM, et al. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (cladribine). Leukemia 1997; 11: 170

    Article  PubMed  CAS  Google Scholar 

  60. Van Den Neste E, Louviaux I, Michaux JL, et al. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br J Haematol 1999; 105: 268–70

    Google Scholar 

  61. Robak T. Second malignancies and Richter’s syndrome in patients with chronic lymphocytic leukemia. Hematology 2004; 9: 387–400

    Article  PubMed  Google Scholar 

  62. Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454–60

    PubMed  CAS  Google Scholar 

  63. Robak T, Blonski JZ, Gora-Tybor J, et al. Second malignancies and Richter’s syndrome in patients with chronic lymphocytic leukemia treated with cladribine. Eur J Cancer 2004; 40: 383–9

    Article  PubMed  CAS  Google Scholar 

  64. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005; 103: 216–28

    Article  PubMed  CAS  Google Scholar 

  65. Pocock C, Matutes E, Wotherspoon A, et al. Fludarabine therapy may precipitate large cell transformation in chronic lymphocytic leukaemia but not in follicular lymphoma [abstract no. 1774]. Blood 1998; 92Suppl. 1: 429a

    Google Scholar 

  66. Giles FJ, O’Brien SM, Keating MJ. Chronic lymphocytic leukemia in Richter’s transformation. Semin Oncol 1998; 25: 117–25

    PubMed  CAS  Google Scholar 

  67. Robertson LE, Pugh W, O’Brien S, et al. Richter’s syndrome: a report on 39 patients. J Clin Oncol 1993; 11: 1985–9

    PubMed  CAS  Google Scholar 

  68. Van den Neste E, Dellanoy A, Feremans W, et al. Second primary tumors and immune phenomena after fludarabine or 2-chloro-2′-deoxyadenosine treatment. Leuk Lymphoma 2001; 40: 541–50

    Article  Google Scholar 

  69. Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–71

    PubMed  CAS  Google Scholar 

  70. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia: updated resuits of the multicenter study of 378 patients. Br J Haematol 2000; 108: 357–68

    Article  PubMed  CAS  Google Scholar 

  71. Keating MJ, O’Brien S, Kantarjian H, et al. Long term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–84

    PubMed  CAS  Google Scholar 

  72. Piro LD, Carrera CJ, Beutler E, et al. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 71: 1069–73

    Google Scholar 

  73. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 433–8

    PubMed  CAS  Google Scholar 

  74. Dearden C, Catovsky D. Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 1990; 62: 4–5

    Article  PubMed  CAS  Google Scholar 

  75. Dillman RO. Pentostatin (nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia. Expert Rev Anticancer Ther 2004; 4: 27–36

    Article  PubMed  CAS  Google Scholar 

  76. Spriano M, Chiorazzi F, Liso V, et al. Multicentre prospective randomized trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-CLL: final report [abstract no. PO86]. Hematol Cell Ther 2000; 42: 93

    Google Scholar 

  77. Jaksic B, Brugiatelli M, Suciu S, et al. Fludarabine versus highdose continuous chlorambucil in untreated patients with B-CLL: results of CLL1 EORTC randomized trial [abstract P096]. Haematol Cell Ther 2000; 42: 97

    Google Scholar 

  78. Dohner H, Fisher K, Bentz M, et al. P 53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–9

    PubMed  CAS  Google Scholar 

  79. Wattel E, Preudhome C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–57

    PubMed  CAS  Google Scholar 

  80. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53 dependent gene expression response. Blood 2004; 104: 1428–34

    Article  PubMed  CAS  Google Scholar 

  81. Begleiter A, Verburg L, Ashique A, et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-B-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9: 1875–81

    PubMed  CAS  Google Scholar 

  82. Koski T, Vilpo L, Vilpo J. Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-B-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia. Leuk Res 1999; 23: 277–9

    Article  PubMed  CAS  Google Scholar 

  83. Tondini C, Balzarotti M, Ramoinelli I, et al. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin’s lymphoma: a phase II randomized study. Ann Oncol 2000; 11: 231–3

    Article  PubMed  CAS  Google Scholar 

  84. Karlsson K, Stromberg M, Jonsson V. Cladribine (CdA) or fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia: first interim analysis of data from the international randomized phase III trial [abstract no. 3470]. Blood 2004; 104Suppl. 1: 945a

    Google Scholar 

  85. Robak T, Bloński JZ, Góra-Tybor J, et al. Cladribine with cyclophosphamide vs. fludarabine with cyclophosphamide as first-line treatment in chronic lymphocytic leukemia: an early report of prospective randomized study (PALG CLL3) [abstract no. 364]. Hematologica Hematol J 2005; 90Suppl. 2: 143–4

    Google Scholar 

  86. Morabito F, Stelitano C, Callea I, et al. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996; 81: 224–31

    PubMed  CAS  Google Scholar 

  87. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056–61

    Article  PubMed  CAS  Google Scholar 

  88. Byrd JC, Peterson B, Piro L, et al. A phase II study of cladribine treatment for fludarabine refractory cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 2003; 17: 323–7

    Article  PubMed  CAS  Google Scholar 

  89. O’Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330: 319–22

    Article  PubMed  Google Scholar 

  90. O’Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis: derived prognostic model for response to treatment. Blood 1993; 82: 1690–700

    Google Scholar 

  91. Robak T, Szmigielska A. Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388. Neoplasma 2000; 47: 168–71

    PubMed  CAS  Google Scholar 

  92. Robak T, Blasinska-Morawiec M, B JZ, et al. The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. Eur J Cancer 1997; 33: 2347–51

    Article  PubMed  CAS  Google Scholar 

  93. Góra-Tybor J, Robak T. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388. Acta Haematol Pol 1993; 24: 177–82

    PubMed  Google Scholar 

  94. Van Den Neste E, Bontemps F, Delacauw A, et al. Potentiation of antitumor effect of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine. Leukemia 1999; 13: 918–25

    Article  CAS  Google Scholar 

  95. Van Den Neste E, Louviaux I, Michaux JL, et al. Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma. Leukemia 2000; 14: 1136–42

    Article  CAS  Google Scholar 

  96. Montillo M, Tedeschi A, O’Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003; 97: 114–20

    Article  PubMed  CAS  Google Scholar 

  97. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002; 3: 244–50

    Article  PubMed  CAS  Google Scholar 

  98. O’Brien S, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414–20

    PubMed  Google Scholar 

  99. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 2001; 14: 342–8

    Article  Google Scholar 

  100. Eichhorst BF, Hopfinger G, Pasold R, et al. Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL): results of a phase III study (CLL 4 protocol) of the German CLL Study Group (GLLL SG) [abstract no. 243]. Blood 2003; 102: 72a

    Google Scholar 

  101. Cazin B, Maloum K, Divine M, et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 75 pts [abstract no. 773]. Blood 2002; 100 (11 Pt 1): 206a

    Google Scholar 

  102. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol 2002; 119: 976–84

    Article  PubMed  CAS  Google Scholar 

  103. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia 2001; 15: 1510–6

    Article  PubMed  CAS  Google Scholar 

  104. Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003; 21: 1278–84

    Article  PubMed  CAS  Google Scholar 

  105. Robak T, Góra-Tybor J, Lech-Marańda E, et al. Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol 2001; 66: 188–94

    Article  PubMed  CAS  Google Scholar 

  106. Robak T, Bloński JZ, Góra-Tybor J, et al. Cladribine alone or in combination with cyclophosphamide or cyclophosphamide and mitoxantrone as first line treatment in chronic lymphocytic leukemia: an early report of a prospective, randomized study [abstract no. 337]. Blood 2004; 104: 100a

    Article  CAS  Google Scholar 

  107. Hallek M, Eichhorst BF. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J 2004; 5Suppl. 1: S20–30

    Article  PubMed  CAS  Google Scholar 

  108. Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 2004; 28: 429–42

    Article  PubMed  CAS  Google Scholar 

  109. Alas S, Bonavida B, Emmanoulides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin’s lymphoma by pentoxifylline and rituximab. Anticancer Res 2000; 20: 2961–6

    PubMed  CAS  Google Scholar 

  110. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800–9

    Article  PubMed  Google Scholar 

  111. Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. Biodrugs 2005; 19: 9–22

    Article  PubMed  CAS  Google Scholar 

  112. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115–20

    Article  PubMed  CAS  Google Scholar 

  113. Savage DG, Cohen NS, Hesdorffer CS, et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 477–81

    Article  PubMed  Google Scholar 

  114. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALG B9712). Blood 2003; 101: 6–14

    Article  PubMed  CAS  Google Scholar 

  115. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukaemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49–53

    Article  PubMed  CAS  Google Scholar 

  116. Keating MJ, O’Brien S, Albitar M, et al. Early results of chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 29: 4079–88

    Article  CAS  Google Scholar 

  117. Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–8

    Article  PubMed  CAS  Google Scholar 

  118. Robak T, Smolewski P, Urbańska-Ryś H, et al. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 2004; 45: 937–44

    Article  PubMed  CAS  Google Scholar 

  119. Tsiara SN, Kapsali HD, Chaidos A, et al. Treatment of resistant/relapsing chronic lymphocytic leukemia with a combination regimen containing deoxycoformycin and rituximab. Acta Haematol 2004; 111: 185–8

    Article  PubMed  CAS  Google Scholar 

  120. Kay E, Geyer SN, Lin T, et al. Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia [abstract no. 339]. Blood 2004, 104; 100a

    Article  CAS  Google Scholar 

  121. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukaemia. Blood 2002; 99: 2245–7

    Article  PubMed  CAS  Google Scholar 

  122. Elter T, Borchmann P, Reiser M, et al. Development of a new four weekly schedule (FluCam) with concomitant application of Campath-1H and fludarabine in patients with relapsed/refractory CLL [abstract no. 2331]. Proc Am Soc Clin Oncol 2003; 22: 580

    Google Scholar 

  123. Rai KR, Byrd JC, Peterson BL, et al. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) Study 199 [abstract no. 772]. Blood 2002; 100Suppl. 1: 205a

    Google Scholar 

  124. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: experience of safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093–101

    Article  PubMed  CAS  Google Scholar 

  125. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971–9

    Article  PubMed  CAS  Google Scholar 

  126. Tedeschi A, Montillo M, Cairoli E, et al. Successful CD34+ priming with intermediate-dose Ara-C (ID Ara-C) in chronic lymphocytic leukemia (CLL) patients treated with sequential fludarabine (FAMP) and Campath-1 H [abstract no. 3277]. Blood 2002; 100Suppl. 1: 830a

    Google Scholar 

  127. Dyer MJ, Kelsey SM, Mackay HJ, et al. In vivo ‘purging’ of residual disease in CLL with Campath-1H. Br J Haematol 1997; 97: 669–72

    Article  PubMed  CAS  Google Scholar 

  128. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695–700

    PubMed  CAS  Google Scholar 

  129. Magnac C, Sutton L, Cazin B, et al. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther 1999; 41: 13–8

    Article  PubMed  CAS  Google Scholar 

  130. Khouri IE, Keating MJ, Saliba MR, et al. Long-term follow-up of patients with CLL treated with allogenic hematopoietic transplantation. Cytotherapy 2002; 4: 217–21

    Article  PubMed  CAS  Google Scholar 

  131. Schultze JL, Donovan JW, Gribben JG. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphotic leukemia. J Mol Med 1999; 77: 259–65

    Article  PubMed  CAS  Google Scholar 

  132. Ritgen M, Bottcher S, Dregor P, et al. Evaluation of minimal residual disease in chronic lymphocytic leukemia. Haematologica Res 2005; 1Suppl. 2: 5–8

    Google Scholar 

  133. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcomes after autologous and allogenic transplantation and correlation with minimal residual disease status. Ann Oncol 1998; 9: 167–77

    Article  PubMed  CAS  Google Scholar 

  134. Sutton L, Maloum K, Gonzalez H, et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia 1998; 12: 1699–707

    Article  PubMed  CAS  Google Scholar 

  135. Pfitzner T, Reiser M, Barth S, et al. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol 2002; 81: 258–66

    Article  PubMed  CAS  Google Scholar 

  136. Clavio M, Miglino M, Spriano M, et al. First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur J Haematol 1998; 61: 197–203

    Article  PubMed  CAS  Google Scholar 

  137. Esteve J, Villamor N, Colomer D, et al. Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution. Ann Oncol 1998; 9: 167–72

    Article  PubMed  CAS  Google Scholar 

  138. Robertson LE, Huh YO, Butler JJ, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic and molecular analysis. Blood 1997; 80: 29–36

    Google Scholar 

  139. Cazin BF, Maloum K, Creteil MD, et al. Oral fludarabine phosphate and cyclophosphamide in previously untreated CLL: final response and follow-up in 75 patients [abstract no. 1598]. Blood 2003; 102: 438a

    Google Scholar 

  140. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol 2002; 119: 976–84

    Article  PubMed  CAS  Google Scholar 

  141. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002; 3: 244–50

    Article  PubMed  CAS  Google Scholar 

  142. Oscier D, Orchard JA, Culligan D, et al. The bioavailability of oral fludarabine phosphate is unaffected by food. Hematol J 2001; 2: 316–21

    Article  PubMed  CAS  Google Scholar 

  143. Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252–8

    PubMed  CAS  Google Scholar 

  144. Rossi JF, van Hoof A, De Boeck K, et al. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2004; 22: 1260–7

    Article  PubMed  CAS  Google Scholar 

  145. Friedberg JW, Dong DA, Li S, et al. Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia and leads to increased STAT1 levels in vivo. Leuk Res 2004; 28: 139–47

    Article  PubMed  CAS  Google Scholar 

  146. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160–6

    PubMed  CAS  Google Scholar 

  147. Karlsson K, Stromberg N, Liliemark J, et al. Oral cladribine for B-cell chronic lymphocytic leukemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients and a long-term follow up of 126 previously treated patients. Br J Hematol 2002; 116: 538–48

    Article  CAS  Google Scholar 

  148. Betticher DC, Ratschiller D, Hsu Schmitz SF, et al. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia. Ann Oncol 1998; 9: 721–6

    Article  PubMed  CAS  Google Scholar 

  149. Samonis G, Kontoyiannis DP. Infectious complications of purine analog therapy. Curr Opin Infect Dis 2001; 14: 409–13

    Article  PubMed  CAS  Google Scholar 

  150. O’Brien S. Infectious complications of nucleoside analogs: hematology. Educational Book of the American Society of Hematology Meeting; 1999 Dec 3–7; New Orleans, 536–42

  151. Anaissie EJ, Kontoyiannis DP, O’Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559–66

    PubMed  CAS  Google Scholar 

  152. Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94: 2033–9

    Article  PubMed  Google Scholar 

  153. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431–48

    PubMed  CAS  Google Scholar 

  154. O’Brien S, Kantarjian H, Beran M, et al. Fludarabine and granulocyte colony stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997; 11: 1631–5

    Article  PubMed  Google Scholar 

  155. Sudhoff T, Arning M, Schneider W. Prophylactic strategies to meet infectious complications in fludarabine treated CLL. Leukemia 1997; 11Suppl. 2: S38–41

    PubMed  Google Scholar 

  156. Byrd JC, Hargis JB, Rester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystic carinii pneumonia prophylaxis. Am J Hematol 1995; 49: 135–42

    Article  PubMed  CAS  Google Scholar 

  157. Robak T, Blonski JZ, Kasznicki M, et al. The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil. Haematologica 2005; 90: 994–6

    PubMed  CAS  Google Scholar 

  158. Balcer AM. The management of leukemia in elderly. Bailliere’s Clin Haematol 1997; 1: 427–48

    Google Scholar 

  159. Spiers ASD. Management of the chronic leukemias: Special considerations in the elderly patient. Part I. Chronic lymphocytic leukemias. Hematology 2001; 6: 291–314

    Google Scholar 

  160. Robak T, Blonski J, Kasznicki M, et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia: final report of the Polish Adult Leukemia Study Group (PALG CLL 1). Med Sci Monit 2005; 11(10): PI71–9

    PubMed  CAS  Google Scholar 

  161. Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 1947–50

    Article  PubMed  CAS  Google Scholar 

  162. Marotta G, Bigazz C, Lenoci M, et al. Low dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85: 1268–70

    PubMed  CAS  Google Scholar 

  163. Robak T, Blasinska-Morawiec M, Bloński JZ, et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1999; 34: 151–7

    PubMed  CAS  Google Scholar 

  164. Thomas DA, O’Brien SM, Kantarjian HM, et al. Re-treatment with fludarabine: outcome of 203 patients with relapsed or refractory CLL treated with salvage therapy [abstract no. PO84]. Hematol Cell Ther 2000; 42: 92

    Article  Google Scholar 

  165. Juliusson G, Liliemark J. Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA induced remission: no acquired resistance. Leuk Lymphoma 1994; 13: 75–80

    Article  PubMed  CAS  Google Scholar 

  166. Robak T, Bloński JZ, Kasznicki M, et al. Re-treatment with cladribine based regimens in relapsed patients with B-cell chronic lymphocytic leukemia: efficacy and toxicity in comparison with previous treatment. Eur J Haematol 2002; 69: 27–36

    Article  PubMed  CAS  Google Scholar 

  167. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: result of a large international study. Blood 2002; 99: 3554–61

    Article  PubMed  CAS  Google Scholar 

  168. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–7

    Article  PubMed  CAS  Google Scholar 

  169. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819–29

    Article  PubMed  Google Scholar 

  170. Schetelig J, Thiede C, Bornhouser M, et al. Evidence for a graftversus leukemia effect in chronic lymphocytic leukemia after reduced intensity conditioning and allogenic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 14: 2747–53

    Article  Google Scholar 

  171. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogenic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004; 32: 28–35

    Article  PubMed  CAS  Google Scholar 

  172. Dreger P, Brand R, Mulligan D, et al. Reduced intensity conditioning lowers treatment related mortality of allogenic stem cell transplantation for chronic lymphocytic leukemia: a population matched analysis. Leukemia 2005; 19: 1029–33

    Article  PubMed  CAS  Google Scholar 

  173. Pensesha S, Milligan DW. Stem cell transplantation for chronic lymphocytic leukemia. Br J Haematol 2005; 128: 145–52

    Article  Google Scholar 

  174. Rizouli V, Gribben JG. The role of stem cell transplantation in chronic lymphocytic leukemia. Semin Hematol 2004; 41: 2416–53

    Article  Google Scholar 

  175. Michallet M, Thiebaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukemias Working Party (CLWP). Br J Haematol 2000; 108: 595–601

    Article  PubMed  CAS  Google Scholar 

  176. Tournilhac O, Cazin B, Lepretre S, et al. Impact of front line fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363–5

    Article  PubMed  CAS  Google Scholar 

  177. Lysak D, Koza V, Steinerova K, et al. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Ann Hematol 2005; 84: 456–61

    Article  PubMed  CAS  Google Scholar 

  178. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993; 50: 292–6

    Article  PubMed  CAS  Google Scholar 

  179. Dreger P, Montserrat E. Autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985–92

    Article  PubMed  CAS  Google Scholar 

  180. Montserrat E. Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. Hematol Oncol Clin N Am 2004; 18: 915–26

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by a grant from the Ministry of Science Warsaw, Poland (No. 2PO51301828). The author has no conflict of interests that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, ul. Pabianicka 62, Lodz, 93513, Poland

    Tadeusz Robak

Authors
  1. Tadeusz Robak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadeusz Robak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robak, T. Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues. Drugs Aging 22, 983–1012 (2005). https://doi.org/10.2165/00002512-200522120-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200522120-00002

Keywords

Search

Navigation